On February 3-4, 2015, a team led by the Qualified Person (QP) of an EU pharmaceutical enterprise conducted a two-day GMP audit of CanSino Biotechnology Inc. This GMP audit was mainly for quality management systems, production equipment and facilities used in the production of human vaccines and biological products.CanSino Biotechnology successfully passed this audit. Through this QP audit, it marks that CanSino has reached a significant milestone in the establishment of quality systems and maintaining high quality standards in the development and manufacturing of vaccine and biological products. 

It is also a key step in the transition from product development to product commercialization.